Registration is now open! Over four days, 20 participants will deepen their knowledge in some of the main fields of nuclear medicine research, with a focus on alpha-emitting radionuclides (astatine-211 especially). They have the opportunity to meet some of the best international experts in radiopharmaceuticals production, artificial intelligence for medical image analysis, and theranostic approaches. Lectures, practical works and visits take place in four major research centres in nuclear medicine in Nantes : Arronax, Faculté des Sciences et des Techniques, Centrale Nantes and Institut de Recherche en Santé. New in 2023 : 4 days of training instead of 3 1 poster session 1 spot per day on nuclear medicine 1 practical session on molecular modeling More about program Looking forward to welcome you in Nantes next July ! The ISI NucMed organization...
Lire plus »
The LabEx IRON would like to congratulate François Guérard, researcher at CRCI2NA Nantes (partner of the LabEx IRON), winner of a Consolidator Grant from the European Research Council (ERC) for his project SAt-Radio: Stable 211At-labeled radiopharmaceuticals for targeted α therapy. From his thesis work (defended in 2010 in Nantes), François Guérard became interested in the chemistry of astatine, an extremely rare element which disintegrates in a few hours and which could destroy many tumors by radioactivity without damaging healthy tissue. He continued on this theme during a first post-doc at the National Cancer Institute (National Institutes of Health, United States). His return to Nantes for a second post-doc funded by the LabEx IRON (March 2014 – September 2017) allows him to persevere in exploring the chemistry of this element as well as other radioactive isotopes of interest in order to make possible their association with biomolecules for diagnostic and therapeutic applications in nuclear medicine. At the end of his two post-docs, François Guérard was recruited Research Fellow at the CNRS in October 2017. The objective of the SAt-Radio project is to explore alternative binding modalities to C-At binding in order to develop new radiolabeling approaches with better in vivo stability. The strategies developed will exploit both the halogen and metallic character of At, using analytical and computational approaches. More information : here This funding rewards François Guérard’s exemplary success in his area of expertise on astate-211. The excellence of its past work has enabled Nantes to place itself among the internationally recognized teams in the field of vectorized alpha therapy and in particular in the use of...
Lire plus »
For the 2nd time in a row, the ILIAD project is labeled SIRIC for 5 years! Supported by Nantes University Hospital, Angers University Hospital & Western Cancer Institute (ICO), the renewal of SIRIC ILIAD by the National Cancer Institute (INCa) is proof of the excellence of the Nantes-Angers research site , integrating medical, scientific & social research in breast cancer and multiple myeloma. For the next 5 years, SIRIC ILIAD’s mission will be to conduct high-level multidisciplinary research, thanks to the know-how of the project partners: Universities, health establishments, associations, engineering schools, research laboratories including CRCI2NA and Arronax members of Labex IRON. Ultimately, the objectives are to succeed in increasing remission and recovery for patients, and to raise awareness among professionals to include and adapt the professional life of patients with...
Lire plus »
Dear Colleagues, As the guest editor of the Special Issue on “Brain Tumors and Their Microenvironment: Focus on Hypoxia, Oxidative Stress and Inflammation” of the International Journal of Molecular Sciences (IJMS, IF 6.208, JCR Q1), I sincerely invite you to contribute a full research article or comprehensive review for peer-review and possible publication. We believe that your work on this extensive and interconnected field could make an excellent contribution to the Issue under development. Special Issue “Brain Tumors and Their Microenvironment: Focus on Hypoxia, Oxidative Stress and Inflammation” https://www.mdpi.com/journal/ijms/special_issues/B1W567O8L6 Keywords of the Special Issue (not limit to): brain tumors tumor microenvironment hypoxia/hypoxic signaling oxidative stress/anti- or pro-oxidants metabolism imaging therapeutics inflammation/immunity radioresistance IJMS has been indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus/SciFinder, and many other databases. Authors who publish with the journal benefit from a short publication time (manuscripts undergo a thorough peer-review process, and a first decision is provided to authors approximately 15.7 days after submission). Your paper would be immediately processed once it’s submitted, and upon acceptance the paper is rapidly published online. Please feel free to contact us or the editorial office (aria.zhu@mdpi.com or ijms@mdpi.com) if you have any questions or concerns. We are looking forward to hearing from you. Best regards, Dr. Myriam Bernaudin Prof. Dr. Natacha Entz-Werlé Guest...
Lire plus »
ICOA conferences in november and december 2022: wednesday 23/11 at 13:30 seminar room of ICOA Dr. Lenuta Profire (University « Grigore T. Popa » Iasi, Romania) « New insights into nonsteroidal anti-inflammatory drugs » thursday 24/11 at 11:00 seminar room of ICOA Dr. Olga Mazuryk (Jagiellonian University, Poland) « Antimetastatic activity of polypyridyl ruthenium(II) complexes – in vitro functional and molecular studies » Dr. Malgorzata Brindell (Jagiellonian University, Poland) « Design new fluorescent turn off-on probes for hypoxia imaging » thursday 01/12 at 10:30 seminar room of ICOA Dr.Gaëlle Blond (Strasbourg University, France) « Syntheses of heterocycles by gold-mediated domino reactions » Contact: Marie-Aude HIEBEL ICOA – UMR 7311 / Université d’Orléans rue de Chartres B.P. 6759 – F-45067 Orléans Cedex 2, France mailto: marie-aude.hiebel@univ-orleans.fr tel: + 33 (0)2 38 49 45 75...
Lire plus »
https://www.sckcen.be/en/events-courses/prismap-training-course-translational-research-radiopharmaceuticals-b53d4628-fd1d-ed11-80e5-ecf4bbc6e827 Registration (free but mandatory) until february 27, 2023 ...
Lire plus »
